A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

NCT07521852 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

HCC - Hepatocellular Carcinoma

Interventions

COMBINATION_PRODUCT: CVM-1118 + Sintilimab + TACE

Sponsor

TaiRx, Inc.